Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07149259

Assessing the Impact of eSight Go At-Home Usage in Individuals With Visual Impairment

This research aims to test the updated version of Gentex's device, eSight Go, an image enhancing wearable device to assist those with vision impairments limiting activities of daily living.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Brooks Rehabilitation

Jacksonville, Florida, 32216, United States

Location status: Recruiting

Location contact

Hannah Grimes

CONTACT

[email protected]

904-528-3159

Katelyn Jordan

PRINCIPAL_INVESTIGATOR

About this study

Subjects will receive introductory training on the controls of the study device at the initial study visit and regular follow-up phone calls once per week from a member of the research staff (e.g., an occupational therapist, or low vision therapist) who is familiar with the study device, to assist with possible troubleshooting as well as device use strategies. You will take the study device home for four weeks to use at school, work, and various daily activities.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 to 90.
  • Best-corrected visual acuity between 20/50 to 20/400 in the better eye.
  • Subjects who have been diagnosed with an ocular condition causing visual impairment
  • Have a functional binocular field of view of at least 20 degrees.
  • Visual status stable for at least six months.
  • Demonstrate visual benefit from magnification.
  • Agree to wear the eSight Go in a variety of situations in the home and community.
  • Score ≥ 20 on the Short Orientation-Memory-Concentration Test of Cognitive Impairment (OMCT).
  • Subject must be able to provide an informed consent
  • Subject must agree to use eSight Eyewear only under conditions that will not jeopardize the safety of either the user or the device.

Exclusion criteria

  • Participant must not be currently undergoing any medical or surgical procedures resulting in unstable vision.
  • Participants who have undergone cataract, refractive, or other surgical procedures related to vision in the six-month period prior to study enrollment.
  • Severe (>20/400) visual impairment in the better seeing eye.
  • Cognitive limitations (< 20 on OMCT).
  • Participants who have undergone any vision-related injections (e.g. anti-VEGF) in the two-month period prior to the study because of active bleeding in the retina. Ongoing anti-VEGF treatments are permitted if the participant is in a "Treat and Extend" or pro re nata ("PRN") disease management, and macula is dry.
  • Participants are unable or unwilling to adhere to the examination schedules as they are described in the study protocol. This may also include participants already enrolled, who for whatever reason, have become unable or unwilling to continue the study. This may also include participants for whom the travel time to/from the study site is unacceptable.
  • Participants who self-report a history of alcoholism, drug abuse, or psychosis.
  • Participants who exhibit clinical evidence of depression, poor motivation, emotional or intellectual problems, or any other conditions which would likely limit validity of consent or appropriate responses to participate in the study or who are deemed unsuitable psychologically or physiologically for study participation by the investigator.
  • Participants who may have a conflict of interest with eSight Corp, which could reasonably influence their participation in the study.
  • Refractive error outside the range correctable by lens inserts in the device (> +/-8.00 D sph or -4.00 cyl)

Treatment and study plan

At Home Use

Device

Participants will take the device home for 4 weeks to use in daily living, such as the home and community settings. There will be regular follow-up phone calls once per week from a member of the research team (e.g., an occupational therapist, or low vision therapist) who is familiar with the device to assist with possible troubleshooting as well as device use strategies. The follow up calls will also collect information about device use time and activities. The device will be returned at visit 2.

Primary outcomes

  1. Change in Visual Acuity

    Time frame: Pre-intervention and post-intervention at 4 weeks

    Early Treatment Diabetic Retinopathy Study Chart (ETDRS) assessing visual acuity. A lower logMAR value indicates an improved score.

  2. Change in Reading Performance

    Time frame: Pre-intervention and post-intervention at 4 weeks

    Minnesota Low Vision Reading Test assessing reading performance. A lower logMAR value indicates an improved score.

Secondary outcomes

  1. Change in Mobility

    Time frame: Pre-intervention and post-intervention at 4 weeks

    Dynamic Gait Index (DGI) assessing the ability of the participant to maintain walking balance. 8 items are scored on a scale of 0 to 4, where 0=severe impairment, 1=moderate impairment, 2=mild impairment, and 3=normal. An increase in score reflects an improvement in mobility.

Study contacts

Contact information is provided by the study sponsor or research team.

Hannah Grimes

CONTACT

[email protected]

904-597-3478

Sponsors and collaborators

Lead sponsor

Brooks Rehabilitation

Other

Registry information

Acronym: eSight

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 29, 2025
Registry last updated
Aug 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.